drugset / Trial / NCT01809912
Safety Study of MG1102 in Patients With Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
To investigate the safety and tolerability of a 28 day course of intravenous (IV) MG1102 in patients with solid tumors for which no standard therapy is available.
Timeline
- Start
- 2010-11
- Primary completion
- 2013-03
- Completion
- 2013-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MG1102 | Protein / enzyme biologic | 6 mg/m2 | Intravenous |
| Subject | MG1102 | Protein / enzyme biologic | 12 mg/m2 | Intravenous |
| Subject | MG1102 | Protein / enzyme biologic | 24 mg/m2 | Intravenous |
| Subject | MG1102 | Protein / enzyme biologic | 48 mg/m2 | Intravenous |
| Subject | MG1102 | Protein / enzyme biologic | 96 mg/m2 | Intravenous |
| Subject | MG1102 | Protein / enzyme biologic | 192 mg/m2 | Intravenous |